Aarti Drugs Ltd vs Kilitch Drugs India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Aarti Drugs Ltd is ₹ 365.2 as of 18 May 15:30 . The P/E Ratio of Aarti Drugs Ltd changed from 23.1 on March 2021 to 18.5 on March 2025 . This represents a CAGR of -4.34% over 5 yearsThe P/E Ratio of Kilitch Drugs (India) Ltd changed from 34.2 on March 2021 to 21.8 on March 2025 . This represents a CAGR of -8.61% over 5 years The Market Cap of Aarti Drugs Ltd changed from ₹ 6475 crore on March 2021 to ₹ 3123 crore on March 2025 . This represents a CAGR of -13.57% over 5 yearsThe Market Cap of Kilitch Drugs (India) Ltd changed from ₹ 125.58 crore on March 2021 to ₹ 581.3 crore on March 2025 . This represents a CAGR of 35.86% over 5 years The revenue of Aarti Drugs Ltd for the Mar '26 is ₹ 721.06 crore as compare to the Dec '25 revenue of ₹ 602.94 crore. This represent the growth of 19.59% The revenue of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 90.1 crore as compare to the Dec '25 revenue of ₹ 55.34 crore. This represent the growth of 62.81% The ebitda of Aarti Drugs Ltd for the Mar '26 is ₹ 96.56 crore as compare to the Dec '25 ebitda of ₹ 56.26 crore. This represent the growth of 71.63% The ebitda of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 22.64 crore as compare to the Dec '25 ebitda of ₹ 7.68 crore. This represent the growth of 194.79% The net profit of Aarti Drugs Ltd changed from ₹ 33.27 crore to ₹ 55.26 crore over 8 quarters. This represents a CAGR of 28.88% The net profit of Kilitch Drugs (India) Ltd changed from ₹ 0.11 crore to ₹ 14.88 crore over 8 quarters. This represents a CAGR of 1063.07% The Dividend Payout of Aarti Drugs Ltd changed from 9.04 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -8.49% over 5 yearsThe Dividend Payout of Kilitch Drugs (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Aarti Drugs Ltd

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
Company also operates Pinnacle Life Science Private Limited, its wholly owned subsidiary focused on formulation development. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

FAQs for the comparison of Aarti Drugs Ltd and Kilitch Drugs (India) Ltd

Which company has a larger market capitalization, Aarti Drugs Ltd or Kilitch Drugs (India) Ltd?

Market cap of Aarti Drugs Ltd is 3,357 Cr while Market cap of Kilitch Drugs (India) Ltd is 534 Cr

What are the key factors driving the stock performance of Aarti Drugs Ltd and Kilitch Drugs (India) Ltd?

The stock performance of Aarti Drugs Ltd and Kilitch Drugs (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Drugs Ltd and Kilitch Drugs (India) Ltd?

As of May 18, 2026, the Aarti Drugs Ltd stock price is INR ₹367.85. On the other hand, Kilitch Drugs (India) Ltd stock price is INR ₹153.0.

How do dividend payouts of Aarti Drugs Ltd and Kilitch Drugs (India) Ltd compare?

To compare the dividend payouts of Aarti Drugs Ltd and Kilitch Drugs (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.